Literature DB >> 21148031

Role of ribosomal protein RPS2 in controlling let-7a expression in human prostate cancer.

Min Wang1, Youji Hu, Michael D Amatangelo, Mark E Stearns.   

Abstract

We discovered that an inverse relationship exists in the expression of ras/c-myc and ribosomal protein RPS2 with pre-let-7a-1/let-7a/let-7f miRNA and prostate tumor cell malignancy. Nonmalignant IBC-10a cells expressed low levels of ras/RPS2 and elevated pre-let-7a-1/let-7a/let-7f miRNA, whereas the reverse occurred in malignant PCa-20a and PC-3ML cells. Stable transfection of IBC-10a cells with pBABE.ras and pBABE.RPS2 induced ras, c-myc, and RPS2 expression, whereas the levels of let-7a/let-7f miRNA dropped to near zero. Conversely, in pBABE.pre-let-7a-1 transfected PCa-20a and PC-3ML clones, let-7a/let-7f increased whereas ras, RPS2, and c-myc dropped greater than 5-fold. Electrophoretic mobility shift assays, antibody "supershift" assays and immunoprecipitation assays revealed that RPS2 specifically binds pre-let-7a-1 to block RNA processing. Immunoflourescent studies and Northern blots confirmed that RPS2 complexes with pre-let-7a-1 (i.e., in episomal structures) to block processing to let-7a/let-7f, indicating RPS2 may prevent let-7a miRNA expression to indirectly promote oncogene expression. Functional studies further showed that the colony-forming ability (CFA) and invasive activities of IBC-10a cells were significantly enhanced in pBABE-ras.IBC-10a and pBABE-RPS2-IBC-10a clones. Conversely, with the "knockdown" of ras and RPS2 in malignant PC-3ML cells (i.e., in pLKO.TRC.shRNA.ras.PC3-ML, pLKO.TRC.shRNA.RPS2.PC-3ML transfected cells), there was both a loss of these functions and a loss of tumorigenesis in SCID mice. Likewise, with the overexpression of let-7a/let-7f in pBABE.pre-let-7a-1.PC-3ML clones (and PCa-20a clones), CFAs, invasive activities in vitro, and tumorigenesis in vivo were significantly reduced. These results show for the first time that RPS2 blocks pre-let-7a-1 processing to enable ras and c-myc expression and the transformation of primary tumor cells. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21148031     DOI: 10.1158/1541-7786.MCR-10-0158

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  6 in total

Review 1.  Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy.

Authors:  Andrea L Kasinski; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2011-11-24       Impact factor: 60.716

2.  Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells.

Authors:  Linlin Zhang; Arun K Lyer; Xiaoqian Yang; Eisuke Kobayashi; Yuqi Guo; Henry Mankin; Francis J Hornicek; Mansoor M Amiji; Zhenfeng Duan
Journal:  Int J Nanomedicine       Date:  2015-04-15

3.  Regulatory Networks of Prognostic mRNAs in Pediatric Acute Myeloid Leukemia.

Authors:  Hao Zhang; Liqin Cheng; Cong Liu
Journal:  J Healthc Eng       Date:  2022-01-05       Impact factor: 2.682

4.  Silencing of long chain noncoding RNA paternally expressed gene (PEG10) inhibits the progression of neuroblastoma by regulating microRNA-449a (miR-449a)/ribosomal protein S2 (RPS2) axis.

Authors:  Jian Zhang; Wei Liu; Ping Ji; Yan Zhang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 5.  Ribosome Biogenesis and Cancer: Overview on Ribosomal Proteins.

Authors:  Annalisa Pecoraro; Martina Pagano; Giulia Russo; Annapina Russo
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

Review 6.  MicroRNAs implicated in the immunopathogenesis of lupus nephritis.

Authors:  Cristen B Chafin; Christopher M Reilly
Journal:  Clin Dev Immunol       Date:  2013-07-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.